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Dyslipidaemia is a major modifi able risk factor for the development of CVD. It is estimated that up to 50% of the European population aged 35-64 years has a total cholesterol >250 mg/dL (6.5 mmol/L). 1 This high prevalence of dyslipidaemia translates into signifi cant cardiovascular morbidity and mortality.
FH is inherited as an autosomal dominant trait, characterised by markedly elevated circulating levels of LDL-C from the time of birth, and subsequent premature atherosclerotic CVD (ASCVD). [2] [3] [4] Heterozygous FH (HeFH) subjects, with total cholesterol levels commonly in the range of 8-15 mmol/L (310-580 mg/dL), typically develop coronary heart disease (CHD) before the age of 55 years (men) and 60 year (women). The prognosis in homozygous FH (HoFH), with total cholesterol levels of 12-30 mmol/L (460-1160 mg/dL), results in very early development of CHD and high mortality rates before the age of 20. 5 The commonly accepted Dutch Lipid Clinic Network (DLCN) criteria 5 may be applied to determine a diagnosis of FH. The DLCN scoring system takes into consideration family history of hyperlipidaemia and premature CHD, personal clinical characteristics of premature CHD, cerebrovascular or peripheral vascular disease, presence of tendinous xanthomata or arcus cornealis, elevated LDL-C and/or an identifi ed mutation. A total point score > 8 is considered 'defi nite' FH, 6-8 is 'probable' FH, and 3-5 is 'possible' FH. 5 
AIMS OF DYSLIPIDAEMIA TREATMENT
LDL-C is the primary target of dyslipidaemia management and is tightly linked to outcomes, providing a reliable and widely used surrogate parameter. The rationale for treatment of dyslipidaemia, particularly elevated LDL-C, derives from extensive clinical trial data in both primary and secondary prevention. Reduction in total cholesterol, non-HDL-C, and (most importantly) LDL-C through pharmacological therapies (particularly statins) lowers the risk of CVD events.
The 2010 Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis, which included 21 randomised trials of statin versus control in almost 130,000 subjects and fi ve trials of more versus less intensive statin regimens in almost 40,000 subjects, confi rmed dose-dependent reduction in CVD with LDL-C lowering treatments. 6 The more intensive regimens resulted in a signifi cant additional proportional risk reduction of 15% in major vascular events, associated with the additional mean LDL-C reduction of 0.51mmol/L. In the meta-analysis of statin versus control, there was a signifi cant risk reduction of 22% with a 1.00 mmol/L LDL-C reduction. 6 The most recent CTT meta-analysis, which focused on whether statin therapy was as effective in women as in men, found similar effectiveness for the prevention of major vascular events in both groups. 7 
CARDIOVASCULAR RISK
Target levels of LDL-C are defi ned by the patient's CV risk. All current guidelines on the prevention of CVD in clinical practice recommend the assessment of clinically evident ASCVD and CV risk. 8 Most guidelines use risk estimation systems based on either the Framingham or the SCORE calculations. [8] [9] [10] However, these systems are not appropriate for FH subjects as such individuals are at considerably higher risk due to their lifelong elevated LDL-C levels and are automatically considered high-risk (HR) as a minimum. 5 
TARGET LDL-C LEVELS
The targeted approach to lipid management is primarily aimed at reducing LDL-C. The most recent ESC/ EAS Guidelines on management of dyslipidaemias recommend an LDL-C goal of <1.8 mmol/L (70 mg/ dL) for subjects at a very high total CV risk. 11 For subjects at high total CV risk, the goal is an LDL-C level <2.6 mmol/L (100 mg/dL). This is a change from the target of <2.5 mmol/L recommended in the previous ESC guidelines.
Given the ASCVD risks associated with FH, reducing the burden of elevated LDL-C levels is critical. [2] [3] [4] [5] However, the extent of underdiagnosis and undertreatment of individuals in the general population with FH is largely unknown across Europe. 5 In Bulgaria, the estimated age-standardised prevalence of potential FH is currently 9% (3.7%-14.2%), based on EUROASPIRE IV analysis. 12 A centralised pan-regional survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in eastern Europe (including Bulgaria, Poland and Russia) reported that the prevalence of FH in subjects on LLT was 1.7%. 13 The rationale for this study was to generate data to provide a robust source of information for physicians concerning the proportion of VHR and HR subjects with FH achieving ESC LDL-C targets in Bulgaria. Prevailing treatment patterns were examined alongside the CV event background of the FH population.
MATERIALS AND METHODS
This was a multicentre, observational study conducted at selected sites across Bulgaria comprising a 13-month retrospective chart review from May 2015 to May 2016 (maximum 396 days).
The study was conducted in accordance with local legal and regulatory requirements, as well as with scientifi c purpose, value and rigour, and followed generally accepted research practices.
All subjects attending the cardiology clinic for a routine visit were screened for eligibility and invited to participate. Adult subjects eligible for the study were those diagnosed with hyperlipidaemia (HR and VHR as defi ned by ESC guidelines) receiving lipid-lowering therapy at the time of enrolment and having at least two LDL-C values recorded for the retrospective data collection period. Subjects who had participated in an interventional clinical trial of hyperlipidaemia treatment were not eligible to enrol into this study.
All data were recorded at the time of subject enrolment, comprising the variables of LDL-C, statin and other lipid modifying therapies, and cardiovascular event history. DLCN criteria were applied to estimate the number with defi nite, probable or possible FH. The presence of tendinous xanthomas was confi rmed by sonographic evaluation, if not visible during the physical examination. CV risk was defi ned at fi rst observation as HR or VHR.
RESULTS
Approximately 24,000 subject records were examined at 12 cardiology sites across Bulgaria. A diagnosis of FH was assumed for 196 subjects (mean age 54.4 years; 64.1% male): 27 defi nite, 94 probable and 75 possible. Subject demographics are shown in Table 1 with distribution concerning the presence of arcus cornealis and tendinous xanthomas between males and females. In addition, 32.7% of subjects were smokers (although no data for LDL-C levels relative to smoking status were collected) and 33.2% were on a low cholesterol diet at baseline.
A breakdown of subjects with FH according to DLCN criteria is shown in Table 2 . In total, 73.6% of subjects with FH had a fi rst-degree relative with known premature coronary and/or vascular disease or known LDL-C above the 95th percentile for age and sex. In addition, 21.8% of subjects had LDL-C levels in the range of 4.0-4.9 mmol/L, 47.7% had LDL-C levels of 5.0-6.4 mmol/L, and 23.2% had LDL-C readings of 6.5-8.4 mmol/L.
According to ESC guidelines, the mean CV risk at baseline was estimated as 59 (26.8%) HR subjects and 161 (73.2%) VHR subjects. Population mean LDL-C was 5.6 mmol/L (SD 1.4 mmol/L) at fi rst observation and 4.1 mmol/L (SD 1.6 mmol/L) at last observation during the 13-month observation period. The minimum observation period was 39 days and the maximal observation period was 395 days.
The number of subjects achieving their ESC LDL-C targets at the end of the observation period is shown in Table 3 . 14.5% of HR subjects achieved the ESC/EAS LDL-C target of <2.5 mmol/L and 5.0% of VHR subjects reached <1.8 mmol/L.
Nearly all subjects (n=219) received statins and 38.6% were prescribed intensive statin therapy (atorvastatin 40-80 mg and rosuvastatin 20-40 mg) during the observation period. Ten percent received combination therapy with a statin plus ezetimibe or other LLT ( Table 4 ). In total, 1.4% (3 subjects) were classifi ed as statin intolerant.
During the study period, 18 (8.2%) subjects with FH were switched to an alternative LLT (including different statin treatments), 43 (19.5%) had their LLT dose or frequency modifi ed and 4 (1.8%) discontinued their LLT completely. The reasons for these changes are shown in Table 5 . The type and incidence of CV events recorded during the observation period are summarised in Table 6 . The most common events occurring were myocardial infarction (STEMI) in 42 (19.1%) subjects and unstable angina pectoris in 48 (21.8%) subjects. Seventy-three subjects (33.2%) received coronary revascularisation.
DISCUSSION

ESC/EAS DEFINED LDL-C TARGETS
The results of this observational study suggest that most subjects with FH in Bulgaria do not reach the ESC/EAS defi ned LDL-C targets. Contributing factors may include suboptimal treatment and underdiagnoses of FH. Presence of arcus cornealis and tendinous xanthomas is distributed equally between males and females. The three subjects with arcus cornealis and one with xanthomas who achieved the ESC target had no recorded CV event (primary prevention). Greater awareness is required concerning the value that systematic physical examination for the presence of tendon and tuberous xanthomas and corneal arcus provides in improving FH diagnosis.
LIPID MANAGEMENT Although statins have proven to be a valuable and effi cacious LDL-C-lowering medication, they may not be suffi cient or appropriate for every patient in need. 14 During the observation period, approximately 30% of subjects had their statin treatment switched or modifi ed (e.g. dosage) and lack of lipid-lowering effi cacy was the principle reason for adjustment of treatment. Some subjects may benefi t from additional or alternative approaches for LDL-C lowering, particularly those with FH. Alternative therapies should be considered for subjects who do not reach their LDL-C target, for example, ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. 14 Only 7.7% of subjects were receiving ezetimibe in combination with their LLT in this study.
The study results indicate that lack of treatment effi cacy may lead to serious comorbidities such as myocardial infarction (STEMI) and unstable angina pectoris. More than one third of subjects (33.2%) required coronary revascularisation during the observation period. However, no baseline CV data were available to compare the incidence of CV events before and after statin treatment.
Studies have shown that, in subjects with HeFH, LDL-C target levels are frequently not reached via statins alone because the baseline levels are very high. In subjects with HoFH with no residual LDLR function, statins do not reduce LDL-C levels at all. In individuals with HoFH with little residual LDLR activity, only modest reductions (10-25 %) in LDL-C serum concentrations are reached, even at the highest doses of the most effi cacious statins. 2, 4, 5 UNDERDIAGNOSES AND INCONSISTENT MANAGEMENT OF FH It has been estimated that, in the majority of countries/territories across the world (approximately 200), less than 1% of subjects with FH are appropriately diagnosed. The few exceptions, where a greater proportion of subjects with FH are diagnosed, comprise the Netherlands (71%), Norway (43%), Iceland (19%), Switzerland (13%), the UK (12%), and Spain (6%). 5 Compared with an extrapolated FH prevalence of an estimated 14-34 million, these First-degree relative with known premature coronary and/or vascular disease (men <55 years, women <60 years) (Or) First-degree relative with known LDL-C above the 95th percentile for age and sex. data strongly suggest that FH is vastly underdiagnosed in most countries. 5 To date, the prevalence of FH has not been assessed directly in an unselected sample from the general population. Management of FH across Europe remains highly variable despite signifi cant efforts to standardise national approaches to treatment in countries such as the UK and Austria. 15 Many countries seem to rely on projects led by patient organisations and charities to drive delivery of screening and treatment programmes. 15 Denmark provides a notable exception. Despite the absence of national guidelines, the Danish healthcare system takes a more proactive approach to FH diagnosis and management, with Coronary heart syndrome 1 (0. lipid clinics at most major hospitals and prevalent prescribing of statins for HR groups over the age of 40 years. 15 In addition, it has recently been demonstrated that early FH diagnosis through cascade testing programmes involving relatives of those with suspected FH is highly cost-effective and may reduce the lifetime costs associated with treatment of FH. 16 The current study highlights that many subjects (73.6%) with FH in Bulgaria have first-degree relatives with known risk factors such as coronary and/or vascular disease or high LDL-C levels, and cascade screening may be of signifi cant benefi t from both a patient outcomes and health economic perspective. However, while some countries such as the Czech Republic offer cascade screening in many areas, implementation of such programmes on a national level is fairly rare across Europe. 16 These results underscore the need to increase awareness of FH among physicians, to promote identifi cation and adequate treatment of these subjects. It is clear that there is an urgent need for improved education and training in relation to the identifi cation of subjects with FH and the optimal treatment options available for those who do not respond to traditional lipid lowering therapies.
CONCLUSION
These study results indicate that most subjects with FH in Bulgaria do not reach the ESC/EAS defi ned LDL-C targets. This may be due, in part, to suboptimal treatment and underdiagnoses of FH caused by a lack of understanding among clinicians concerning the risk factors and appropriate management of this condition. Greater awareness is required concerning the value of systematic physical examination in improving FH diagnosis and optimal approaches to lipid management that aim to improve effi cacy and minimise development of serious comorbidities, such as STEMI and unstable angina pectoris. 
